Kyntra Bio to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Globe Newswire (Wed, 2-Sep 7:30 AM ET)
Analysts’ Top Healthcare Picks: Kyntra Bio (KYNB), Arrowhead Pharmaceuticals (ARWR)
TipRanks (Tue, 1-Sep 6:40 AM ET)
Wall Street Analysts Are Neutral on Top Healthcare Picks
TipRanks (Mon, 31-Aug 9:10 PM ET)
Kyntra Bio Streamlines Financing, Strengthens Balance Sheet
TipRanks (Mon, 31-Aug 5:52 PM ET)
Globe Newswire (Mon, 31-Aug 4:05 PM ET)
Kyntra Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
Globe Newswire (Thu, 13-Aug 4:02 PM ET)
Kyntra Bio to Report Second Quarter 2026 Financial Results
Globe Newswire (Thu, 6-Aug 9:00 AM ET)
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.
Kyntra Bio trades on the NASDAQ stock market under the symbol KYNB.
As of September 3, 2026, KYNB stock price declined to $8.49 with 12,306 million shares trading.
KYNB has a market cap of $34.35 million. This is considered a Sub-Micro Cap stock.
Last quarter Kyntra Bio reported $-1 million in Revenue and -$4.68 earnings per share. This fell short of revenue expectation by $-3 million and missed earnings estimates by -$1.50.
The top ETF exchange traded funds that KYNB belongs to (by Net Assets): VTI, VXF.
KYNB support price is $8.19 and resistance is $8.87 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that KYNB shares will trade within this expected range on the day.